924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On January 14, 2026, Boston Scientific entered a Merger Agreement under which Penumbra will merge into a Boston Scientific subsidiary and become a wholly owned subsidiary. Penumbra stockholders can elect $374.00 in cash or 3.8721 Boston Scientific shares per share, subject to proration that sets 73.26% of shares for cash and 26.74% for stock. Completion depends on Penumbra stockholder approval, antitrust and other regulatory clearances, and other conditions, and the filing excerpt ends before the full termination terms are described.
Cash election: $374.00 per Penumbra share; stock election: 3.8721 Boston Scientific shares per Penumbra share
Proration: 73.26% of Penumbra shares receive cash and 26.74% receive Boston Scientific stock
Penumbra equity awards: $274.00 in cash plus 1.0353 Boston Scientific shares, measured against a 10-day average trading price
Penumbra would pay Boston Scientific a $525,000,000 termination fee in specified circumstances
STAAR Surgical entered a cooperation agreement with Broadwood Partners, its largest stockholder, which owns 31% of common stock. Under the deal, the board expanded from six to seven, CEO Stephen Farrell and director Elizabeth Yeu resigned, and three Broadwood-linked nominees joined the board. The company also said it is no longer in compliance with Nasdaq's three-member audit committee rule and intends to use a cure period.
Farrell's CEO service ends January 31, 2026, or earlier if the board decides; he will serve as a consultant for one year at $45,000 per month
Farrell is eligible for 18 months of base salary and insurance premium reimbursement, subject to a general release
Yeu's resignation leaves the audit committee below the three-independent-director minimum; the company notified Nasdaq on January 14, 2026
Broadwood agreed not to request a special stockholder meeting until June 18, 2026
Genuine Parts Company said non-executive Chairman Paul D. Donahue will retire from the board at the end of his term at the 2026 annual shareholder meeting. The board has appointed CEO Will Stengel as chairman effective upon Donahue's retirement, so Stengel will hold the combined Chairman and CEO roles, which consolidates leadership at the top of the company.
Paul D. Donahue, non-executive Chairman, retires from the board at the end of his term at the 2026 annual shareholder meeting.
Will Stengel, President and CEO since June 2024, is appointed chairman effective upon Donahue's retirement.
Upon Donahue's retirement, Stengel will serve as both Chairman and Chief Executive Officer.
The filing does not report any financial results or guidance changes.
Penumbra agreed on January 14, 2026 to merge with Boston Scientific, which will acquire it in a deal valued at $374 per share and an enterprise value of approximately $14.5 billion. The same day, Penumbra released preliminary fourth quarter and full year 2025 revenue that grew 17.3% to 17.5% for the year, and the merger requires Penumbra stockholder approval and other closing conditions.
Each Penumbra share can be exchanged for $374 in cash or 3.8721 Boston Scientific shares, subject to proration to about 73% cash and 27% stock.
Boston Scientific expects to finance the approximately $11 billion cash portion with cash on hand and new debt.
The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary conditions, and Penumbra stock would be delisted from the NYSE.
Preliminary full year 2025 revenue of $1,401.3 million to $1,403.1 million, up 17.3% to 17.5%; fourth quarter revenue of $383.0 million to $384.8 million, up 21.4% to 22.0%.
Talen Energy agreed to acquire the Lawrenceburg, Waterford and Darby gas-fired plants, about 2.6 gigawatts of capacity in Ohio and Indiana, from Energy Capital Partners for $3.45 billion. The price is about $2.55 billion in cash, which Talen expects to fund with new debt, plus 2.4 million new Talen shares to ECP. The deal is expected to close early in the second half of 2026, subject to regulatory approvals, and the company says it will be accretive to adjusted free cash flow per share.
Purchase price of $3.45 billion: about $2.55 billion in cash and about $900 million in Talen stock (2.4 million shares)
ECP would own about 5% of pro forma combined Talen equity, per the company's estimate
Expected close early in the second half of 2026; requires HSR waiting period expiration and approvals from FERC and the Indiana Utility Regulatory Commission
Resale of the new shares is to be covered by a registration rights agreement, with 90-day and 180-day lock-ups
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.